8-K current report · filed Aug 10, 2026

Amneal Pharmaceuticals, Inc. (AMRX) 8-K Current Report: August 10, 2026

Item 2.01Item 2.03Item 7.01Item EX-99.1Item 1.01Item 3.02AMRX overview

Short answer

Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.03 (Creation of a Direct Financial Obligation), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities). $350 million incremental term loan from Bank of America funded acquisition consideration.

Amneal Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $350 million incremental term loan from Bank of America funded acquisition consideration
  • Debt increase raises leverage and future interest obligations, with repayment terms governed by the amended credit agreement
  • Stockholders Agreement amended to recognize acquisition-related stock consideration in Amneal Group ownership calculations
  • Ownership amendment may affect voting power, governance rights and control-related provisions for the Amneal Group

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Item 2.01 indicates a completed acquisition or disposition, with transaction details contained in the filing’s Introductory Note
  • Investors should review the Introductory Note for assets involved, consideration paid or received, and expected strategic impact

Item 2.03 · Creation of a Direct Financial Obligation

  • Direct financial obligation details are contained in the filing’s Introductory Note and Item 1.01
  • Investors should review the related agreement for borrowing amount, pricing, maturity and repayment obligations

Item 3.02 · Unregistered Sales of Equity Securities

  • Amneal issued 28,942,098 Class A shares to acquisition sellers as stock consideration
  • Transaction used Securities Act Section 4(a)(2) private-placement exemption, avoiding immediate public registration
  • Planned Form S-3 resale registration creates potential future selling pressure from sellers
  • Registration statement due by the later of 30 days after closing or 10 business days after seller information receipt

Item 7.01 · Regulation FD Disclosure

  • Amneal completed the Acquisition, marking a transition from announced transaction to closed deal
  • Exhibit 99.1 press release contains transaction details and expected strategic implications
  • Investors should assess acquisition funding, integration requirements, and potential effects on future financial results

Item EX-99.1 · Exhibit EX-99.1

  • Completed Kashiv acquisition, creating an integrated biosimilars platform spanning R&D, manufacturing, and commercialization
  • Biosimilars become a major long-term growth pillar, extending Amneal’s growth profile into the 2030s
  • Access to global biologics market facing more than $300 billion of projected loss-of-exclusivity over the next decade
  • Combined portfolio expected to support multiple biosimilar launches annually
  • Key execution risks: Kashiv integration, regulatory approvals, commercialization timing, competition, pricing pressure, and Amneal’s indebtedness

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Amneal Pharmaceuticals, Inc. 8-K filings

Get the next AMRX 8-K as it lands

Follow AMRX for push alerts, or ask the research agent what this filing means.